SHL Telemedicine Ltd. (SHLT)
| Market Cap | 189.80M |
| Revenue (ttm) | 59.00M |
| Net Income (ttm) | -76,000 |
| Shares Out | 15.86M |
| EPS (ttm) | -0.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127 |
| Open | 11.13 |
| Previous Close | 11.97 |
| Day's Range | 11.13 - 11.97 |
| 52-Week Range | 8.31 - 51.81 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SHLT
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central... [Read more]
Financial Performance
In 2022, SHLT's revenue was $59.00 million, an increase of 18.99% compared to the previous year's $49.58 million. Losses were -$76,000, -99.46% less than in 2021.
Financial StatementsNews
SHL Telemedicine to Commence Trading on NASDAQ Under the Symbol "SHLT"
Listing on the SIX Swiss Exchange to continue in parallel to the NASDAQ listing ZURICH and TEL AVIV , March 31, 2023 /PRNewswire/ -- SHL Telemedicine Ltd. ("SHL", SIX Swiss Exchange: SHLTN), a leading...